Clinical implications for the administration of colony stimulating factors.
This article familiarizes the practitioner with the clinical nursing implications of the colony stimulating factors that have been approved for use. The process of hematopoiesis is reviewed with a focus on the mechanisms of action for Sargramostim, Filgrastim, and Epoetin Alfa. Each agent is discussed individually and information is presented regarding indications, pharmacologic properties, routes of administration, and potential adverse reactions. Nursing interventions for care of the patient receiving colony stimulating factors are discussed.
Schneider
S M
SM
D003115:Colony-Stimulating Factors / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use*; D004921:Erythropoietin / Q000494:pharmacology / Q000627:therapeutic use; D006410:Hematopoiesis / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D009732:Nursing Care
D003115:Colony-Stimulating Factors; D004921:Erythropoietin